Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	592
Overall Study	STARTED	4200 mg Bamlanivimab	588
Overall Study	Received at Least One Dose of Study Drug	Placebo	587
Overall Study	Received at Least One Dose of Study Drug	4200 mg Bamlanivimab	588
Overall Study	Prevention Population	Placebo	485
Overall Study	Prevention Population	4200 mg Bamlanivimab	487
Overall Study	Treatment Population	Placebo	68
Overall Study	Treatment Population	4200 mg Bamlanivimab	66
Overall Study	Serology Positive	Placebo	36
Overall Study	Serology Positive	4200 mg Bamlanivimab	35
Overall Study	COMPLETED	Placebo	493
Overall Study	COMPLETED	4200 mg Bamlanivimab	521
Overall Study	NOT COMPLETED	Placebo	99
Overall Study	NOT COMPLETED	4200 mg Bamlanivimab	67

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04497987/flow